LAUSR

gangrenosum in the biologic era, the response to therapy. Aliment Pharmacol Ther 2013; 38: 563–572. 4 Jaimes-L opez N, Molina V, Arroyave JE et al. Development of pyoderma gangrenosum during therapy with infliximab. J Dermatol Case Rep 2009; 3: 20–23. 5 Fiorino G, Danese S, Pariente B et al. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving antiTNF-a agents. Autoimmun Rev 2014; 13: 15–19. 6 Rozenbaum M, Boulman N, Slobodin G et al. Polyarthritis flare complicating rheumatoid arthritis infliximab therapy: a paradoxic adverse reaction. J Clin Rheumatol 2006; 12: 269–271. 7 Takahashi T, Asano Y, Shibata S et al. Arthritis possibly induced and exacerbated by TNF antagonist in a patient with psoriasis vulgaris. Br J Dermatol 2015; 172: 1458–1460. 8 Lee M, Petroniene R, Thorne C. New onset of inflammatory polyarthritis in a patient taking adalimumab. J Rheumatol 2009; 36: 660. 9 Van RD, Mooij JE, Baeten DL et al. New-onset polyarthritis during successful treatment of hidradenitis suppurativa with infliximab. Br J Dermatol 2011; 165: 194–198. 10 Villani AP, Weiler L, Jullien D et al. Paradoxical psoriatic arthritis in a patient with rheumatoid arthritis treated by TNFa blocker. Joint Bone Spine 2014; 81: 455–456.